May 28, 2024 – Page 9 – Goldea Capital

Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8® in ALS (ACT-EAP)

Written by Customer Service on May 28, 2024. Posted in Public Companies.

First patient, first visit is planned for early June 2024 Enrollment has been expanded by 80% to a maximum of 180 participants ‘Real-world’ drug efficacy data will be collected by monitoring potential drug effects on survival and disease progression, as well as safety SALT LAKE CITY, May 28, 2024 (GLOBE NEWSWIRE) — Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly-owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced several key updates on its National Institutes of Health (NIH)-funded Accelerating Access to Critical Therapies Expanded Access Program (ACT-EAP) for CNM-Au8®...

Abeona Therapeutics to Present at the Jefferies Global Healthcare Conference

Written by Customer Service on May 28, 2024. Posted in Public Companies.

CLEVELAND, May 28, 2024 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its senior management team will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 11:30 a.m. Eastern Time. The Company will also participate in one-on-one investor meetings at the conference. A live webcast of the fireside chat will be available on the Investors section of the Abeona website under “Events” at https://investors.abeonatherapeutics.com/events. The webcast will be archived for 30 days. About Abeona Therapeutics Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Prademagene zamikeracel (pz-cel) is Abeona’s investigational autologous, COL7A1 gene-corrected epidermal...

Venus Concept Announces $35 million Debt-to-Equity Exchange Transaction

Written by Customer Service on May 28, 2024. Posted in Public Companies.

Substantial Reduction of Existing Debt by Madryn Asset Management to Support Restructuring Efforts and Compliance with NASDAQ Listing Requirements TORONTO, May 28, 2024 (GLOBE NEWSWIRE) — Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that, on May 24, 2024, the Company exchanged $35.0 million of its senior debt held by affiliates of Madryn Asset Management, LP (“Madryn”) for 576,986 shares of newly-created Series Y preferred stock. Each share of Series Y preferred stock is convertible into common stock on a 1-for-100 basis at the option of the holder at any time, or automatically upon the Company’s completion of a $30.0 million common equity raise, subject to certain other conditions. The debt-to-equity exchange represents a significant reduction...

TG Therapeutics Announces Schedule of Upcoming Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting

Written by Customer Service on May 28, 2024. Posted in Public Companies.

NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming presentations highlighting study designs for post-marketing studies being undertaken for BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, being held May 29 – June 1, 2024, in Nashville, Tennessee. Abstracts are now available online and can be accessed on the CMSC meeting website at www.mscare.org/2024 or by clicking on the following link: https://meridian.allenpress.com/ijmsc/article/26/s1/1/500896/Abstracts-from-the-38th-Annual-Meeting-of-the. Details for the upcoming BRIUMVI presentations are outlined below. Poster Presentation Title: A Post-Marketing Study Evaluating the Presence and Concentration...

Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD

Written by Customer Service on May 28, 2024. Posted in Public Companies.

SAN FRANCISCO and WALTHAM, Mass., May 28, 2024 (GLOBE NEWSWIRE) — Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease (COPD) and other inflammatory and immunology (I&I) indications, today announced that Lisa Bollinger, MD, has been appointed to the company’s board of directors. Dr. Bollinger most recently served as Vice President, Regulatory Affairs, Global Regulatory Affairs and Clinical Safety (GRACS) at Merck, where she led the general medicine therapeutic area in regulatory affairs. Dr. Bollinger’s over 30 years of experience in drug development, with deep regulatory experience gained both within the U.S. FDA and multinational biotechnology and pharmaceutical companies contributed...

Agrify Corporation Regains Compliance with Nasdaq Stockholders’ Equity Requirement

Written by Customer Service on May 28, 2024. Posted in Public Companies.

TROY, Mich., May 28, 2024 (GLOBE NEWSWIRE) — Agrify Corporation (Nasdaq:AGFY) (“Agrify” or the “Company”), a leading provider of innovative cultivation and extraction solutions for the cannabis industry, today announced that after the recent $13.8 million debt-to-equity conversions by CP Acquisitions, LLC and GIC Acquisition, LLC, two entities affiliated with Raymond Chang, Chairman and CEO of Agrify, Agrify has received confirmation from Nasdaq that it has regained compliance with the stockholders’ equity requirement of minimum of $2.5 million in Listing Rule 5550(b)(1). “We are very thankful that Nasdaq has confirmed that Agrify has regained compliance with the minimum stockholders’ equity requirement. The $13.8 million debt-to-equity conversion is a very significant commitment from the management and the leading shareholders...

Opthea Completes Enrollment in Pivotal Phase 3 Clinical Program with Sozinibercept in Wet AMD

Written by Customer Service on May 28, 2024. Posted in Public Companies.

Phase 3 program enrolled 1,984 patients across COAST and ShORe trials Trials designed to replicate superiority in visual outcomes demonstrated in Phase 2b Topline data from both pivotal trials expected in mid-CY2025 MELBOURNE, Australia and PRINCETON, N.J., May 28, 2024 (GLOBE NEWSWIRE) — Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that it has now completed enrollment in both the COAST and ShORe trials constituting its pivotal Phase 3 clinical program. This program is designed to assess the safety and superior efficacy of sozinibercept in combination with standard-of-care anti-VEGF-A therapies compared to standard...

Yorbeau Consolidates Interest in Its Beschefer Property

Written by Customer Service on May 28, 2024. Posted in Public Companies.

MONTREAL, May 28, 2024 (GLOBE NEWSWIRE) — Yorbeau Resources Inc. (TSX: YRB) (the “Company” or “Yorbeau”) is pleased to announce that it has completed the acquisition of the remaining 20% undivided interest (the “Minority Interest”) in certain mining claims comprising a portion of the Company’s Beschefer property. The Beschefer property is located in northwestern Quebec, approximately 140 kilometers northwest of the town of La Sarre and 190 kilometres west of Matagami (Figure 1). The Beschefer property covers an area of approximately 4,075 hectares and is composed of 128 claims. Yorbeau already held a 100% interest in all of these claims, except for the 65 claims that were subject to the Minority Interest. Further to the acquisition of the Minority Interest, Yorbeau owns a 100% interest in all the Beschefer property, subject to...

Leading Proxy Advisor ISS Recommends Medallion Shareholders Vote “FOR” Both of the Board’s Director Nominees on the BLUE Proxy Card

Written by Customer Service on May 28, 2024. Posted in Public Companies.

Also Recommends in Favor of Say-on-Pay NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) — Medallion Financial Corp. (NASDAQ: MFIN) (“Medallion” or the “Company”) today announced that leading independent proxy advisory firm Institutional Shareholder Services (“ISS”) has recommended that Medallion shareholders vote on the BLUE proxy card “FOR” ONLY the two incumbent candidates nominated by the Board of Directors, Robert M. Meyer and David L. Rudnick and “FOR” the advisory vote on the compensation of the Company’s named executive officers in connection with the Company’s 2024 Annual Meeting of Shareholders (the “Annual Meeting”). The Annual Meeting will be held on June 11, 2024. In its report issued on May 24, 2024, ISS noted: “The company’s TSR has outperformed its peers and the broader market over the one-, three-, and...

KANZHUN LIMITED repurchased RMB74 million ordinary shares under its repurchase plan

Written by Customer Service on May 28, 2024. Posted in Public Companies.

BEIJING, May 28, 2024 (GLOBE NEWSWIRE) — KANZHUN LIMITED (“BOSS Zhipin” or the “Company”), a leading online recruitment platform in China, recently announced that the Company has implemented a repurchase plan and repurchased nearly 1 million ordinary shares with a total value of more than RMB74 million. Earlier last week, the Company announced its unaudited financial results for the quarter ended March 31, 2024. The Company’s main operating indicators, such as revenues, total paid enterprise customers and average monthly active users, all reached record highs in the first quarter. Revenues for the first quarter of 2024 were RMB1,703.8 million (US$236.0 million), an increase of 33.4% from RMB1,277.5 million for the same quarter of 2023. This exceeded the Company’s previous expectations. Adjusted net income remained healthy....

Day: May 28, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice